Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight,
BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined
whether canagliflozin decreases albuminuria and reduces renal function decline
independently of its glycemic effects in a secondary analysis of a clinical trial in 1450
patients with type 2 diabetes receiving metformin and randomly assigned to either once-
daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6–8 mg. End …